Global Cardiac Mapping Market

Cardiac Mapping Market Size, Share, Growth Analysis, By End user(Hospitals & Clinics, Diagnostic Centers, and Others), By Product(Contact Cardiac Mapping Systems, and Non-Contact Cardiac Mapping Systems), By Indication(Atrial Fibrillation, Atrial Flutter, AVNRT, And Others), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35A2783 | Region: Global | Published Date: July, 2024
Pages: 219 | Tables: 90 | Figures: 73

Cardiac Mapping Market News

  • In September 2022, Biosense Webster, a subsidiary of Johnson & Johnson Medtech, announced Octore, a topographic catheter designed to simplify the imaging of uncomplicated coronary heart disease A new eight-wire catheter stands out challenges electrophysiologists to accurately model conditions such as atrial fibrillation (AFib). To simplify the task The eighth, which holds promise, appears as a wonderful addition to the growing field of cardiac imaging technology, offering potential benefits for increased accuracy and efficiency in the diagnosis and treatment of simple heart failure.
  • In April 2022, a clinical trial aimed at determining the precise locations of NOAF delivery and rotors after cardiac surgery was initiated at the University Hospital of Basel, Switzerland Trial by computer so used a combination of low-dose tomography scan and non-invasive side mapping, including CardioInsightTM - 3D Mapping Prou ​​The doctor benefited Sponsored by the University Hospital, so this approach highlights the promise of advancing cardiac imaging techniques.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardiac Mapping Market size was valued at USD 1.86 billion in 2022 and is poised to grow from USD 2.03 billion in 2023 to USD 4.01 billion by 2031, growing at a CAGR of 8.90% during the forecast period (2024-2031).

The competitive environment of the Cardiac Mapping market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Biosense Webster (U.S.)', 'Boston Scientific Corporation (U.S.)', 'Medtronic (Ireland)', 'Abbott (U.S.)', 'BIOTRONIK (Germany)', 'MicroPort Scientific Corporation (China)', 'Acutus Medical Inc. (U.S.)', 'Catheter Precision (U.S.)', 'Koninklijke Philips N.V. (Netherlands)', 'EP Solutions (Switzerland)', 'Lepu Medical Technology Co. Ltd. (China)', 'AngioDynamics (U.S.)', 'BioSig Technologies (U.S.)', 'APN Health (U.S.)', 'CoreMap (U.S.)', 'Kardium (Canada)', 'Epmap-System (Germany)'

The anticipated growth in market revenue for cardiac mapping systems is underpinned by two key factors: the rising likelihood of an increase in cardiovascular disorders and the continuous technological advancements in cardiac mapping diagnostics. According to the World Health Organisation (WHO), cardiovascular diseases (CVDs) stand as the leading cause of mortality, responsible for approximately 17.9 million deaths annually. Notably, more than four out of every five CVD-related fatalities are attributed to heart attacks and strokes, with a significant proportion occurring in individuals under the age of 70.

During the forecast period, the cardiac imaging market is expected to witness substantial growth driven by multiple factors. Medical device companies are expected to play a key role in this trend as cutting-edge diagnostic technologies are increasingly adopted. Increasing demand for accurate cardiac testing has been identified as another major driver The growth is great because of its expansion.

The North American cardiac mapping market is poised to assert its dominance, driven by several key factors. The region's leading position is attributed to the high prevalence of Cardiovascular Diseases (CVDs), a health concern that has prompted an increasing acceptance rate of cardiac mapping systems in the United States. The validation of these systems through clinical trials further contributes to the robust demand growth anticipated over the forecast period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cardiac Mapping Market

Report ID: SQMIG35A2783

$5,300
BUY NOW GET FREE SAMPLE